Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin’s Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation
Open Access
- 28 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Background: Among the growing number of patients with hematologic neoplasms hospitalized in the intensive care unit (ICU), the largest proportion of these patients are diagnosed with lymphoma. However, less attention has been paid in the past to identifying critically ill patients and assessing the prognosis of patients in ICU. Traditional critical care-related scores have shown limitations and inaccuracy in predicting mortality risk. Methods: Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) were searched for in the Marketplace for Information in Intensive Care Medicine III (MIMIC-III) database. We searched mortality within 28 days as the primary endpoint. Logistics regression was used to screen risk factors. A calibration curve was used for internal validation, and the ROC curve and AUC were used to compare the new model with traditional scores. Results: 405 patients with DLBCL are enrolled in the project. Multivariate analysis shows the patients with the level of lactate dehydrogenase (LDH) > 327 U/L had an increased risk of 28-day mortality in ICU than others (OR = 13.04, pConclusions: The elevated level of LDH indicates a poor prognosis of patients with DLBCL in the ICU. Our risk score with crossed validation based on the level of LDH shows a significant prognostic value and may be a valuable tool for assessing the critically ill as well.Keywords
This publication has 21 references indexed in Scilit:
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLOS Medicine, 2015
- Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studiesActa Oncologica, 2015
- Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating CellsCell Metabolism, 2014
- Targeting lactate metabolism for cancer therapeuticsJournal of Clinical Investigation, 2013
- Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated PatientsClinical Cancer Research, 2012
- Pathogenesis of Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2011
- Dual Roles of Immune Cells and Their Factors in Cancer Development and ProgressionInternational Journal of Biological Sciences, 2011
- High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agentsEuropean Journal of Haematology, 2010
- Aggressive LymphomasNew England Journal of Medicine, 2010
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993